Heide L. Ford

Affiliations: 
Molecular Biology University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
Area:
Oncology, Molecular Biology
Google:
"Heide Ford"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Anantharajan J, Zhou H, Zhang L, et al. (2019) Structural and functional analyses of an allosteric Eya2 phosphatase inhibitor that has on target effects in human lung cancer cells. Molecular Cancer Therapeutics
Oliphant MUJ, Vincent MY, Galbraith MD, et al. (2019) Six2 mediates late-stage metastasis via direct regulation of Sox2 and induction of a cancer stem cell program. Cancer Research
Neelakantan D, Zhou H, Oliphant MUJ, et al. (2018) Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications. 9: 4720
Zhang L, Zhou H, Li X, et al. (2018) Author Correction: Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications. 9: 3830
Vartuli RL, Zhou H, Zhang L, et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. The Journal of Clinical Investigation
Zhang L, Zhou H, Li X, et al. (2018) Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications. 9: 1047
Zhou H, Zhang L, Vartuli RL, et al. (2017) The Eya phosphatase: Its unique role in cancer. The International Journal of Biochemistry & Cell Biology
Neelakantan D, Zhou H, Oliphant MUJ, et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications. 8: 15773
Dimberg L, Towers CG, Behbakht K, et al. (2017) A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Molecular Cancer Research : McR
Kendrick AA, Schafer J, Dzieciatkowska M, et al. (2016) CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget
See more...